About 12 results found for searched term "sPLA2 inhibitor" (0.131 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M8168 | sPLA2 inhibitor | Phospholipase |
| Secretory phospholipase A2 inhibitor blocks the activation of NF-κB, Akt, p38 MAPK and ERK pathways. | ||
| M50994 | sPLA2-IIA Inhibitor | Others |
| sPLA2-IIA Inhibitor is a cyclic pentapeptide analog of FLSYK (cyclic 2-Nal-Leu-Ser-2-Nal-Arg (c2)), that binds to hGIIA (human IIA phospholipase A2) and inhibits its hydrolytic ability. | ||
| M56768 | sPLA2-X Inhibitor 31 | Phospholipase |
| sPLA2-X Inhibitor 31 is a selective secreted phospholipase A2 type X (sPLA2-X) inhibitor with IC50s of 26 nM, 310 nM, and 2230 nM for sPLA2-X, sPLA2-IIa, and sPLA2-V, respectively. | ||
| M7894 | LY311727 | Others |
| LY311727 is an oral active compound; Phospholipase A2 (sPLA2; Group activity highlights) inhibitors. | ||
| M10916 | RO 46-8443 | Endothelin Receptor |
| RO 46-8443 is the first non-peptide endothelin ETB receptor selective antagonist. RO 46-8443 displays up to 2000-fold selectivity for ETB receptors both in terms of binding inhibitory potency and functional inhibition. | ||
| M14515 | Varespladib methyl | Phospholipase |
| A-002; LY333013 | ||
| Varespladib methyl (A-002; LY333013) is a selective inhibitor of group II secretory phospholipase A2 (PLA2). | ||
| M27936 | BI-9627 | Na+/H+ Exchanger (NHE) |
| BI-9627 is potent sodium-hydrogen exchanger isoform 1 (NHE1) inhibitor, with IC50s of 6 and 31 nM in intracellular pH recovery (pHi) and human platelet swelling assays, respectively. BI-9627 displays >30-fold selectivity against NHE2 and with no measurable inhibitory activity against the NHE3 isoform. BI-9627 shows low DDI (agent-agent interaction) potential, excellent pharmacokinetics in rat and dog, and remarkably potent activity in the isolated heart model of ischemia-reperfusion injury. | ||
| M28121 | SPR inhibitor 3 | Others |
| SPRi3 | ||
| SPR inhibitor 3 (SPRi3) is a potent sepiapterin reductase (SPR) inhibitor. SPR inhibitor 3 (SPRi3) displays high binding affinity to human SPR in a cell-free assay (IC50=74 nM) and efficiently reduces biopterin levels in a cell-based assay (IC50=5.2 μM). SPR inhibitor 3 (SPRi3) reduces neuropathic and inflammatory pain through a reduction of BH4 levels. | ||
| M28388 | BI-9627 hydrochloride | Na+/H+ Exchanger (NHE) |
| BI-9627 hydrochloride is potent sodium-hydrogen exchanger isoform 1 (NHE1) inhibitor, with IC50s of 6 and 31 nM in intracellular pH recovery (pHi) and human platelet swelling assays, respectively. BI-9627 hydrochloride displays >30-fold selectivity against NHE2 and with no measurable inhibitory activity against the NHE3 isoform. BI-9627 hydrochloride shows low DDI (agent-agent interaction) potential, excellent pharmacokinetics in rat and dog, and remarkably potent activity in the isolated heart model of ischemia-reperfusion injury. | ||
| M28835 | Me-Indoxam | Phospholipase |
| Me-Indoxam is a potent and cell-impermeable secreted phospholipase A2 (sPLA2) inhibitor. | ||
| M28836 | Varespladib sodium | Phospholipase |
| LY315920 sodium | ||
| Varespladib sodium (LY315920 sodium) is a potent and selective group IIA, secretory phospholipase A2 (sPLA2) inhibitor with an IC50 of 9 nM. Varespladib sodium exhibits the significant inhibitory effect on sPLA2 activity in serum from various species including rat, rabbit, guinea pig and human with IC50s of 8.1 nM, 5.0 nM, 3.2 nM and 6.2 nM, respectively. | ||
| M54671 | BTX-6654 | PROTAC |
| BTX-6654 is a targeted and specific cerebellar-based bifunctional SOS1 PROTAC degrader.BTX-6654 reduces the downstream signaling markers pERK and pS6 and displays antiproliferative activity in a wide range of KRAS-mutant cells. In two KRAS G12C xenograft models, BTX-6654 degraded SOS1 in a dose-dependent manner correlating with tumor growth inhibition, additionally exhibiting synergy with KRAS and MEK inhibitors. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
